boston scientific stock: BSX overview & key data

Boston Scientific (BSX) — Stock overview

Keyword notice: This article focuses on the equity meaning of the term boston scientific stock (NYSE: BSX). It is not about tokens, cryptocurrencies or other uses.

As of Jan 25, 2026, according to AP market coverage and Benzinga market data, boston scientific stock (ticker: BSX) is the publicly traded common equity of Boston Scientific Corporation, listed on the New York Stock Exchange (NYSE). This article explains what investors and beginners need to know about the company, where to find market data and filings, key metrics reported in recent market snapshots (price, market cap, short interest), and the main business, growth drivers, and risks that commonly matter to market participants.

Why read on: you will get a clear primer on Boston Scientific as a traded company, verified market facts as of the reporting date, and a structured checklist of resources and filings to check before making any decisions.

Company and business overview

Boston Scientific Corporation is a U.S.-headquartered medical-device company that designs, develops and manufactures products used in interventional medical specialties. Its products support minimally invasive procedures across multiple clinical areas. The company organizes its business around procedure-driven product categories and sells globally through a combination of direct sales forces and distribution partners.

Primary product and therapy areas include:

• MedSurg (procedural technologies used in general surgery, endoscopy and related interventions).
• Cardiovascular (stents, catheters, electrophysiology systems and implantable devices).
• Notable products and technologies mentioned in investor conversations: WATCHMAN family for left atrial appendage occlusion, electrophysiology systems (including pulsed field ablation approaches), and neuromodulation therapies.

Boston Scientific sells to hospitals, health systems and physicians worldwide and competes with other major medical-device companies across implantable and disposable product lines. The company’s results are sensitive to procedural volumes, device adoption, regulatory approvals and reimbursement environments in major markets.

Ticker, exchange and identifiers

• Ticker: BSX
• Exchange: New York Stock Exchange (NYSE)
• ISIN: US1011371077 (company-registered ISIN)
• CUSIP: 101137107 (commonly cited CUSIP for U.S. equities; verify in official filings)
• Other identifiers: data vendors publish additional IDs (FIGI, SEDOL, Bloomberg/Reuters identifiers) — check the company’s investor relations or your data provider for the exact codes used on a platform-by-platform basis.

Note: identifiers may be displayed differently across platforms; always verify the ISIN/CUSIP against company filings when precise matching is required for settlement or institutional workflows.

Market data and trading information

Where to find live price, charts and market-data items

Investors use major market-data providers and brokerage platforms to view live price and charts for boston scientific stock. Typical market-data items that matter to traders and investors include last trade (last price), market capitalization, daily volume, bid/ask quotes, intraday high/low and historical price series. Options markets and institutional liquidity are also important for some participants.

Trading hours and liquidity

• Primary market: NYSE U.S. regular trading hours (generally 09:30–16:00 ET), with pre-market and after-hours sessions available via many broker platforms.
• Liquidity: BSX is a large-cap medical-device stock with regular institutional interest and available options — liquidity is typically sufficient for retail and many institutional trades, though spreads and depth can vary intraday.

Bitget note: for users who prefer a single provider for market data and trading experience, Bitget provides market-data tools and trading products; check Bitget’s product list for U.S. equities-related services and available instruments (availability may vary by jurisdiction).

As of Jan 25, 2026, market snapshot (reported by AP/Benzinga): last trades and intraday ranges for BSX clustered near $91 per share in multiple market prints; market capitalization reported around $135.61 billion in third-party market summaries.

Price performance and historical ranges

• Intraday snapshot (Jan 25, 2026): intraday high prints for BSX in AP/Benzinga summaries were around $92.40 with intraday lows near $90.44; last prints reported in aggregated feeds clustered near $91.20–91.70 per share.

• Long-term performance: public market summaries cited in market data reports show that boston scientific stock has delivered materially positive long-term returns in some historical windows; for example, one market summary reported a 10‑year annualized return of approximately 18.03% and an outperformance versus broad market indexes of ~4.48% annualized over that decade. (As always, confirm exact return periods and calculations from a trusted data provider.)

• Volatility and beta: medical-device equities can show moderate volatility tied to procedure volume cycles, regulatory outcomes and sector rotations; individual beta and volatility metrics are published by major data vendors and will change over time.

Financials and key metrics

Reporting cadence and where to confirm numbers

Boston Scientific files quarterly (10‑Q) and annual (10‑K) reports with the U.S. Securities and Exchange Commission and publishes earnings releases and investor presentations via its investor-relations channel. For exact, up-to-date figures (revenue, net income, EPS, margins), refer to the most recent 10‑Q/10‑K and the latest earnings release. This article avoids presenting stale or potentially inaccurate hard-dollar figures and instead points you to where to verify those numbers.

Commonly cited metrics investors watch for boston scientific stock:

• Revenue (quarterly and trailing twelve months)
• Net income and diluted earnings per share (EPS)
• Adjusted EBITDA and operating income
• Gross margin and operating margin trends
• Price-to-earnings ratio (P/E) on trailing and forward EPS
• Free cash flow (FCF) and cash conversion metrics

Fiscal year end and reporting rhythm

Boston Scientific operates on a calendar-year fiscal schedule; confirm exact fiscal-year-end date and the company’s investor day schedule in the latest investor-relations communications.

Balance sheet and cash flow highlights

When evaluating boston scientific stock, investors commonly assess: debt levels (gross and net), cash and short-term investments, and free cash flow generation. Medical-device firms often carry elevated R&D and acquisition-related spending; key items to check in the balance sheet include long-term debt maturities and available liquidity to fund operations and M&A.

For verified, numerical balance-sheet snapshots and cash-flow trends (debt-to-equity, net cash/levered debt, trailing free cash flow), use the company’s most recent 10‑Q/10‑K and management’s capital-allocation commentary.

Business segments and growth drivers

Boston Scientific’s revenue is driven by procedure volumes and adoption of newer devices and technologies. Two high-level segments that often frame investor discussions are:

• MedSurg: product families used in endoscopy, neuromodulation and other surgical procedures. Growth drivers include minimally invasive procedure adoption and new device launches.
• Cardiovascular: implantable devices, electrophysiology systems (including pulsed field ablation — PFA) and structural-heart solutions (e.g., WATCHMAN). Growth here tends to come from new device approvals, clinical adoption and expanded indications.

Other growth drivers and considerations:

• Product innovation: new device approvals or label expansions can materially affect procedure adoption curves.
• Procedure volumes: hospital procedural activity (cardiac procedures, electrophysiology ablations, structural interventions) drives device demand.
• Geographic expansion: sales in developed markets (U.S., Europe) and growth in emerging markets are tracked separately by management.
• M&A and bolt-on acquisitions: the company has historically used acquisitions to add technology and expand addressable markets.

Recent corporate actions and news (as of reporting date)

As of Jan 25, 2026, market reporting highlights for boston scientific stock include:

• Market snapshots and active-trader feeds (AP/Benzinga) showing intraday price prints near $91 and ongoing trading volume in the millions of shares across U.S. exchanges on the reporting date.
• Short interest data reported in market summaries: there were approximately 20.01 million shares sold short, representing about 1.36% of the publicly available float — an increase of ~4.62% vs. the prior short-interest report. Based on recent average trading volume, reported days-to-cover were about 2.37 days. (Reporting: Benzinga automated market summary; see “As of Jan 25, 2026, according to Benzinga” below.)

Sources and timeliness

• Market snapshots and most-active lists used in this summary were aggregated in AP market coverage and Benzinga market-data feeds with prints dated Jan 25, 2026.
• For company announcements such as FDA approvals, M&A deals or earnings releases, check Boston Scientific’s investor-relations press releases and SEC filings for the official corporate record.

Analyst coverage and investor sentiment

Institutional analysts and broker research teams typically publish consensus ratings, forward revenue and EPS estimates, and price targets. Aggregators consolidate these into visible consensus ratings (buy/hold/sell mixes) and mean/median price targets.

What to look for in analyst coverage for boston scientific stock:

• Consensus catalysts cited by analysts (e.g., new product adoption, procedural volume recovery, margin expansion, or successful integration of acquisitions).
• Range of price targets to understand upside/downside expectations in analyst models.
• Changes in coverage: upgrades, downgrades or material revisions often drive intraday price action.

Where to check aggregated analyst data: financial-data platforms provide consolidated analyst ratings and price-target ranges; institutional clients also use brokerage research directly. Aggregated commentary is useful for sentiment context but always check the underlying assumptions.

Dividends, share repurchases and capital allocation

• Dividend policy: as of the reporting date and company disclosures, Boston Scientific’s primary capital-allocation emphasis has historically been on re-investment in R&D, strategic acquisitions and share repurchases rather than a high cash dividend. Confirm the current dividend policy in the company’s investor-relations materials.
• Share repurchases: the company has engaged in buybacks in past years as part of capital allocation. Investors monitor outstanding buyback authorizations, repurchase pace and the effect on diluted shares outstanding.

Capital-allocation considerations include balancing organic R&D, targeted M&A and returning capital to shareholders via buybacks or dividends when appropriate.

Share ownership and float

• Institutional holders and mutual funds typically own meaningful stakes in large-cap medical-device firms; major institutional ownership is commonly reported in 13F filings and public share‑ownership summaries.
• Short interest snapshot (Jan 25, 2026): ~20.01 million shares sold short (≈1.36% of float) with days-to-cover ≈2.37, reflecting modest short activity compared with some high-short-interest names. This short-interest figure had risen ~4.62% since the previous reporting period in the market summary referenced.

Investors pay attention to float, shares outstanding, insider holdings and institutional concentrations because these affect liquidity and potential price moves during news-driven events.

Corporate governance and management

Key governance items investors typically review for boston scientific stock:

• Executive leadership: profiles of the CEO, CFO and heads of major business segments; management’s tenure and track record on product development, M&A integration and capital allocation.
• Board composition: independence, relevant industry experience and committee structures (audit, compensation, governance).
• Investor relations: the company provides contact and resource materials for investors — use those official IR channels for direct communications and primary documents.

For biographies and up‑to‑date governance materials, consult the company’s investor-relations disclosures and proxy statements.

Risks and regulatory considerations

Investing in any medical-device company carries sector-specific risks. For boston scientific stock, the commonly cited risk categories are:

• Regulatory approvals and clearances: failure to obtain or maintain regulatory approvals (e.g., FDA in the U.S.) for new devices or label expansions can delay or limit market access.
• Reimbursement and health‑care policy: device adoption depends on payer coverage and reimbursement rates in major markets.
• Litigation and product liability: medical-device companies face product liability and class-action risks; litigation outcomes can be material.
• Competition: other large medtech firms and new entrants compete on technology, price and physician adoption.
• Supply-chain and manufacturing: device manufacturing requires supply precision and quality controls; supply disruptions or recalls can affect sales and margins.
• Macroeconomic sensitivity: procedure volumes can be cyclical and sensitive to healthcare utilization trends.

Investors should monitor regulatory filings, recall notices, and legal disclosures in the company’s SEC filings for concrete details on ongoing litigation or material contingencies.

Valuation and investment considerations

Common valuation approaches applied to boston scientific stock include:

• Price-to-earnings (P/E) on trailing and forward EPS
• Enterprise-value-to-EBITDA (EV/EBITDA)
• Discounted cash flow (DCF) for detailed long-term cash-flow assumptions

Key valuation debates investors track:

• Premium vs. cyclical multiple: is the stock priced for durable above-market growth driven by successful device launches, or is the multiple sensitive to cyclicality in procedure volumes?
• Growth assumptions: expected adoption of new technologies (e.g., PFA in electrophysiology or broader uptake of structural-heart devices) vs. execution risk and competition.

This article presents neutral education on commonly used valuation frameworks; for model inputs and precise valuations, use current earnings estimates and market prices from your data provider.

Options, derivatives and institutional trading

• Options availability: BSX usually has listed options across standard monthly expirations and weekly expirations for some strikes; options can be used for hedging, income generation (covered calls) and directional trading.
• Institutional strategies: large institutions may hold BSX via direct equity, index funds and sector ETFs; portfolio managers may use derivatives for risk management.

When considering options or derivatives, ensure you understand contract specifications and margin/clearing requirements from your broker.

Reporting, filings and investor resources

Where to find authoritative documents for boston scientific stock:

• SEC EDGAR: company 10-Q and 10-K filings for audited financial statements and risk-factor disclosures.
• Earnings releases and investor presentations: company-published material summarizes quarter-over-quarter results and management commentary.
• Earnings call transcripts: management and analyst Q&A provide context on strategy and near-term expectations.
• Investor FAQs and corporate governance filings: for shareholder procedures and governance details.

As of Jan 25, 2026, reference the company’s official investor-relations materials for the latest documents and archived earnings presentations.

Historical stock events

Investors often refer to material, stock-related milestones when assessing long-term performance. Examples of events that historically affect share price include:

• Major acquisitions that expand product portfolios or enter new therapy areas.
• FDA approvals or regulatory setbacks for key devices.
• Large, unexpected litigation settlements or recalls.
• Notable share-repurchase programs or special dividends.
• Historical IPO/split events (for earlier company history).

For Boston Scientific’s specific historical milestones (IPO date, major acquisitions and historical splits), consult company historical investor documents and SEC filings.

Short-interest detail (market snapshot)

As of Jan 25, 2026, according to market-data reporting summarized in Benzinga-generated feeds:

• Short interest: approximately 20.01 million shares sold short.
• Short interest as % of float: ~1.36%.
• Change since last report: short interest rose by ~4.62%.
• Days to cover (based on average trading volume): ~2.37 days.

Why this matters: changes in short interest are an indicator of near-term sentiment among traders. A rising short-interest level can reflect increased bearish positioning, while a falling short interest can signal short-covering or reduced bearishness. These statistics are one piece of market information and should be used alongside other fundamental and market-data checks.

Source attribution: "As of Jan 25, 2026, according to Benzinga's market-data summaries and AP most-active lists." (Reporting date and sources are noted to maintain timeliness.)

Comparable tickers and industry context

Common peer companies include other medical-device and implantable-device manufacturers. When building peer comparisons, investors look at metrics such as revenue growth, margin profile, R&D intensity, and valuation multiples to understand relative positioning.

Peer comparisons are often constructed from 10-K peer lists or by selecting companies with similar product mixes and scale.

How retail and beginner investors can follow boston scientific stock

Actionable, non-investment steps beginners can take (informational):

1. Track price and volume on a reputable market-data platform or brokerage (Bitget users can check Bitget market tools where available).
2. Read the most recent 10-Q and latest earnings release on the company’s investor-relations page.
3. Review key metrics: market cap, shares outstanding, float, recent revenue and EPS trends, and short-interest figures.
4. Monitor regulatory news (FDA approvals, device clearances) and major product announcements.
5. Use educational materials on options and derivatives before trading options tied to BSX.

Reminder: This is informational only — not investment advice.

Investor checklist before further research

• Verify the latest market price and volume for boston scientific stock on a live feed (date-stamped).
• Pull the most recent 10‑Q/10‑K for verified financial figures.
• Confirm short-interest levels and days-to-cover from an exchange-reported source.
• Review recent management commentary from the latest earnings call transcript.
• Check regulatory and legal disclosures for pending matters that could be material.

Useful data points from Jan 25, 2026 market summaries (reporting context)

• Intraday prints and most-active lists aggregated by AP and Benzinga showed Boston Scientific prints near $91 per share on multiple U.S. exchange feeds the morning of Jan 25, 2026.
• Market capitalization reported in a Benzinga market summary: approximately $135.61 billion (reported in automated content cited by market-data feeds).
• Short interest, days-to-cover and the small percentage of float sold short (1.36%) were reported by Benzinga’s aggregated short-interest summary.

Reporting note: these items are time-stamped market-data snapshots; market prices and derived metrics (market cap, days-to-cover) change intraday and across reporting cycles.

Where to confirm primary source documents

• Boston Scientific investor relations (press releases, investor presentations, archived earnings slides).
• U.S. SEC filings (EDGAR) for 10‑Q, 10‑K, 8‑K and proxy statements.
• Exchange-reported short-interest figures for formal short-interest reports.
• Major data providers for live pricing, consensus estimates and analyst coverage.

Final notes and next steps

Further exploration: if you want to track boston scientific stock over time, bookmark the company’s investor relations, subscribe to official earnings-release alerts and use a trusted market-data platform for real-time price and volume monitoring.

If you prefer a single platform to view market data and perform trades where permitted, consider checking Bitget’s available market tools and instrument list for U.S. equity market data services and supported products. Bitget provides consolidated market-data displays and trading workflows for users in supported jurisdictions — confirm availability and regulatory eligibility in your country.

To reiterate, this article is informational and neutral. For precise, time-stamped numeric figures, always confirm with the company’s filings and primary market-data feeds.

Further explore: review the latest 10‑Q and earnings transcript, monitor regulatory news, and check exchange-reported short-interest filings for the next periodic update.

Reporting date and sources: As of Jan 25, 2026, market-data snapshots and short-interest summaries referenced in this article were reported in AP market lists and Benzinga market-data feeds. For official corporate announcements and financial statements, consult Boston Scientific’s investor-relations disclosures and SEC filings.

Disclaimer: The information contained here is neutral reference material about boston scientific stock (NYSE: BSX). It is not investment advice, a recommendation, or an offer to buy or sell any securities. Verify all figures and consult qualified professionals before acting.